Ruxolitinib prevents STAT3-phosphorylation (Figure 2D) while increasing IRAK4/NFκB/p38-signaling in CLL cells in vitro (Figures 2B and 3B) and in vivo (Figure 1) (13). The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.